Rapid Micro Biosystems (NASDAQ:RPID) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Rapid Micro Biosystems (NASDAQ:RPID) released its quarterly earnings data on Friday. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03), FiscalAI reports. Rapid Micro Biosystems had a negative return on equity of 131.52% and a negative net margin of 145.81%.The company had revenue of $8.05 million for the quarter, compared to analysts’ expectations of $7.88 million.

Here are the key takeaways from Rapid Micro Biosystems’ conference call:

• Second-quarter revenue rose 11% year over year to $8.1 million, exceeding guidance, with four Growth Direct Systems placed and nine validations completed. The company reached its 200th system placement milestone and reported record quarterly consumable revenue.
• Recurring revenue increased 14% to $5.0 million, supported by a larger installed base and higher system utilization, while consumable revenue grew more than 20%. Management expects further consumable and service growth in the second half.
• Gross margin improved to a record 15% from 4% a year earlier, driven by cost reductions, manufacturing efficiencies, service productivity, and operating leverage. The company expects at least 20% gross margin in Q3 and mid- to high-20% margins in Q4.
• Rapid Micro reaffirmed 2026 revenue guidance of $37 million to $41 million and system-placement guidance of 30 to 38 systems, while raising validation guidance to at least 27 systems. Management also expects a meaningfully stronger contribution from its MilliporeSigma collaboration in the second half.
• The company reported a $12.9 million quarterly net loss and ended the quarter with approximately $20 million in cash and short-term investments. Although cash usage is expected to decline, Rapid Micro remains dependent on cost reductions, improved operating performance, potential debt-facility tranches, and warrant proceeds to support its path to positive cash flow.

Rapid Micro Biosystems Price Performance

Shares of Rapid Micro Biosystems stock traded down $0.35 during trading on Friday, hitting $1.73. 1,443,479 shares of the company were exchanged, compared to its average volume of 204,342. Rapid Micro Biosystems has a fifty-two week low of $1.66 and a fifty-two week high of $4.94. The company has a quick ratio of 1.66, a current ratio of 2.57 and a debt-to-equity ratio of 0.93. The firm has a 50 day moving average price of $1.90 and a 200 day moving average price of $2.67. The stock has a market capitalization of $79.87 million, a price-to-earnings ratio of -1.54 and a beta of 1.44.

Institutional Investors Weigh In On Rapid Micro Biosystems

A number of hedge funds and other institutional investors have recently modified their holdings of RPID. Vanguard Group Inc. raised its position in shares of Rapid Micro Biosystems by 6.7% in the third quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock valued at $3,223,000 after buying an additional 60,655 shares during the last quarter. Geode Capital Management LLC boosted its position in Rapid Micro Biosystems by 6.3% during the fourth quarter. Geode Capital Management LLC now owns 217,568 shares of the company’s stock worth $631,000 after acquiring an additional 12,881 shares during the last quarter. 683 Capital Management LLC purchased a new stake in Rapid Micro Biosystems in the 4th quarter worth approximately $350,000. Millennium Management LLC acquired a new position in Rapid Micro Biosystems in the 4th quarter valued at $338,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Rapid Micro Biosystems by 4.9% during the 4th quarter. Renaissance Technologies LLC now owns 115,627 shares of the company’s stock worth $335,000 after purchasing an additional 5,440 shares during the period. 52.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on RPID shares. Lake Street Capital lowered their price target on Rapid Micro Biosystems from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, May 22nd. KeyCorp dropped their price target on Rapid Micro Biosystems from $8.00 to $5.00 and set an “overweight” rating for the company in a research report on Friday, May 29th. Wall Street Zen upgraded shares of Rapid Micro Biosystems from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $6.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.